- Home
- CYTO
as 11-15-2024 4:00pm EST
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
| Founded: | 2003 | Country: | Bermuda |
| Employees: | N/A | City: | N/A |
| Market Cap: | 2.2M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 106.0K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.91 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $17.20 | Next Earning Date: | 09-24-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Altamira Therapeutics Ltd. News
CYTO Breaking Stock News: Dive into CYTO Ticker-Specific Updates for Smart Investing
GlobeNewswire
a month ago
Altamira Therapeutics Provides Update on Nasdaq Listing
GlobeNewswire
2 months ago
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
GlobeNewswire
2 months ago
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
GlobeNewswire
2 months ago
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
GlobeNewswire
2 months ago
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
GlobeNewswire
2 months ago
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
GlobeNewswire
2 months ago
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
GlobeNewswire
2 months ago
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
Compare CYTO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CYTO Altamira Therapeutics Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.